<DOC>
	<DOCNO>NCT00245960</DOCNO>
	<brief_summary>To assess efficacy two different treatment regimen etanercept psoriasis subject psoriatic arthritis respect skin joint manifestation .</brief_summary>
	<brief_title>Study Evaluating Etanercept Skin Joint Disease Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>18 year age old time consent Active Psoriatic Arthritis Clinically stable , plaque psoriasis involve 10 % body surface area Evidence skin condition psoriasis would interfere skin examination . Systemic antipsoriasis therapy DMARD within 28 day study drug initiation Prior exposure TNFinhibitor , include etanercept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Skin Disease</keyword>
	<keyword>Joint Disease</keyword>
</DOC>